Molecular Testing in Lung Cancer for Determination of Patient Eligibility for Targeted Therapies

Medical Director, Molecular Oncology
Dr. Bernard is a professor of pathology at the University of Utah School of Medicine. He received his MD from and completed his postdoctoral training at the University of Utah and is certified in clinical pathology by the American Board of Pathology. Dr. Bernard’s laboratory at the Huntsman Cancer Center utilizes comprehensive genomic analyses to identify and translate biomarkers into clinical care for cancer patients. His work in gene expression classification of breast cancer led to the development of PAM50 (Prosigna), an FDA-approved diagnostic offered worldwide. His current research are in the development of liquid biopsies using ctDNA, CTCs, and exosomes for monitoring and early detection of cancer.
Chief, Division of Anatomic and Molecular Oncologic Pathology
Dr. Bronner is a Carl R. Kjeldsberg presidential endowed professor of pathology at the University of Utah School of Medicine. Dr. Bronner received her MD from the University of Pennsylvania and completed her pathology residency training and chief residency at the Hospital of the University of Pennsylvania in Philadelphia. Dr. Bronner’s honors include her election as president of the GI Pathology Society, election as council member of the United States and Canadian Academy of Pathology, and, in 2005, the award of the Arthur Purdy Stout Prize, recognizing her work as a surgical pathologist under the age of 45 whose research publications have had a major impact on diagnostic pathology. Dr. Bronner is an editorial journal board member for Human Pathology and Modern Pathology. She has served as an investigator on numerous NIH and foundation grants over the course of her career and has published more than 100 peer-reviewed articles and numerous book chapters.
Medical Director, Cytopathology
Dr. Chadwick is an associate professor of anatomic pathology at the University of Utah School of Medicine. She received her MD at Loma Linda University in California where she also served as a pathology fellow. Dr. Chadwick completed her residency in anatomic and clinical pathology at the University of Utah School of Medicine and was a cytopathology fellow at the University of Washington in Seattle. She is a member of the United States and Canadian Academy of Pathology, American Society of Cytopathology, and College of American Pathologists. Dr. Chadwick’s research interests include the use of molecular markers in cytopathology, pancreatic and biliary cancer, and cervical cancer screening.
Medical Director, Surgical Pathology and Molecular Oncology
Dr. Grossmann received a BS in zoology at the College of Idaho and a PhD and MD from the Oregon Health Sciences University, where she studied tyrosine kinase substrate specificity with Brian J. Druker, MD. Dr. Grossmann completed both a residency in anatomic pathology and a research fellowship in molecular medicine at the University of Utah. Her postdoctoral work in the laboratory of Dean Y. Li, MD, PhD, focused on the role of small GTPases in melanoma invasion and metastasis. Most recently, Dr. Grossmann completed a fellowship in molecular genetic pathology at ARUP Laboratories. Her primary subspecialty interests are sarcoma pathology and molecular oncology. Her research interests include mechanisms of tumorgenesis, metastasis, and the development of targeted therapies for cancer treatment.
Medical Director, Anatomic Pathology
Dr. Samowitz is a professor of pathology at the University of Utah School of Medicine. He received his MD from SUNY Downstate, and completed residency training in anatomic pathology at the University of Chicago and fellowships in gastrointestinal pathology at Johns Hopkins Hospital. Specializing in gastrointestinal pathology and the molecular genetics of colorectal cancer, Dr. Samowitz is also the medical director for numerous molecular tests in solid tumor molecular diagnostics, including single-gene assays and next-generation sequencing panels.